MassBio’s latest Biopharma Funding Report shows Massachusetts biopharma companies raised record-breaking $5.8 billion in VC Funding in 2020.
MassBio today released its 2020 Massachusetts Biopharma Funding Report, which shows that the Massachusetts biopharma industry experienced its best funding year on record. In 2020, venture capital investment in Massachusetts biopharma companies reached $5.8 billion, surpassing 2018’s previous recorded high of $4.8 billion.
In addition, 21 Massachusetts biotech companies went public in 2020, a 110% increase from 2019, totaling $3.9 billion raised. These Massachusetts companies accounted for 32% of all United States-based biotech IPOs by volume. Additionally, two Massachusetts biotechs went public through a special purpose acquisition company (SPAC) merger in 2020, representing 50% of all United States-based biotech SPAC mergers in 2020.
The report also found that Cambridge, Massachusetts remains a driving force within the life sciences industry. Cambridge-based biopharma companies received 55% of all biotech VC investment in Massachusetts and raised 63% of all IPO money.
To download the full report, click here.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.